Pancreatic Cysts - Guidelines Based Management

AdventHealth

V. Shami

How Recent Data Impacts Pancreatic Cancer Management

Integrity CE

M. Pishvaian

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Pract…

2024 ESMO Annual Meeting Insights Hub

H. Babiker

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: …

Yale Cancer Center

M. Cecchini

ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancrea…

2024 ESMO Annual Meeting Insights Hub

D. Melisi

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

2024 ASCO® Annual Meeting Insights Hub

E. Dotan

ASCO® GI 2025 Insights: Phase 1b Study of Gemcitabine & Nab-Paclitax…

Insights from 2025 ASCO® GI Annual Meeting

S. Pant

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

L. Zheng

Cancer Screening Molecular Tools

Fengting Yan

Updates in Perioperative Therapy of Pancreatic Cancer

Horizon CME

P. Philip

Pancreatic Adenocarcinoma and Neuroendocrine Tumors - An Update

AdventHealth

M. Tejani

ASCO® GI 2025 Insights: Neoadjuvant mFOLFIRINOX vs. Gem/nab-Paclitax…

Insights from 2025 ASCO® GI Annual Meeting

K. Dhamija

Pancreatic Cancer Risk in Prediabetic Individuals

Akhil Jain

Targeting KRAS in Pancreatic Cancer

Harshabad Singh

ASCO® 2024 Summary: "Advancing GI Cancer Treatment - The Clinical Ut…

2024 ASCO® Annual Meeting Insights Hub

S. Cohen

NORPACT-1 Trial Updates: Neoadjuvant FOLFIRINOX vs. Upfront Surgery …

Yale Cancer Center

J. Lacy

Updates From SIOG Annual Meeting 2024: Treatment of Pancreatic Cance…

OncoAlert

E. Soto Perez De Celis